Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trebananib in Persistent/Recurrent Endometrial Cancer
NCT01210222Phase 2Completed
- Sponsor
- GOG Foundation
- Start
- Jun 2011
- Primary completion
- Jul 2016
- Modality
- Peptides, Antibody-Based Therapeutics, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of trebananib in endometrial carcinoma, sponsored by GOG Foundation. Started Jun 2011; status: completed.
02
Drugs
trebananib
03
Conditions
endometrial carcinoma
Beyond the preview
Go deeper on NCT01210222.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01210222.